Healthcare Costs Associated With Anabolic Steroid Use: A Cohort Study
Scandinavian Journal of Medicine & Science in Sports · 2026
DOI: 10.1111/sms.70206 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Scandinavian Journal of Medicine & Science in Sports, 2026. Verfasst von Henrik Horwitz und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Health Care Costs, Anabolic Agents, Testosterone Congeners. Die Arbeit nennt 30 Literaturangaben. Gefördert von: Anti Doping Danmark.
Abstract (Originalsprache)
Anabolic androgenic steroid (AAS) use is associated with various health risks, yet its impact on healthcare expenditures remains insufficiently explored. This nationwide register‐based study examined direct healthcare costs among 1183 males sanctioned for AAS use in Denmark between 2006 and 2017, compared with 59 150 age‐ and sex‐matched controls from the general population. Healthcare costs were calculated across primary care, hospital services, and prescription drugs, with up to 10 years of follow‐up. AAS users had significantly higher total healthcare costs, with a mean excess of 3299 euros (EUR) per person (95% CI: 1857–4742; p < 0.0001) over the follow‐up period, corresponding to approximately EUR 537 per AAS user per year. This represents a 45% increase over controls, whose average total costs were EUR 7393 per person. The cost difference was primarily driven by hospital care but was also evident in primary care and prescription medication use. Cumulative cost differences increased steadily over time and remained consistent across most diagnostic categories. AAS users were relatively young and otherwise expected to have low healthcare use, suggesting a notable health burden in this group. These findings add real‐world evidence on the healthcare implications of AAS use and highlight a sustained cost difference between AAS users and controls over a prolonged period. Continued follow‐up may be necessary to fully capture long‐term costs, particularly as some complications may appear years after use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacology, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark.
- Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
- Nordic Institute of Health Economics, Aarhus, Denmark.
ORCID-Profile: Henrik Horwitz
Förderung
- Anti Doping Danmark
Zitieren
APA
Horwitz, H., Olesen, R. H., Windfeld-Mathiasen, J., Dalhoff, K. P., Andersen, J. T., Middelboe, M., Ehlers, L. H., & Heerfordt, I. M. (2026). Healthcare Costs Associated With Anabolic Steroid Use: A Cohort Study. Scandinavian Journal of Medicine & Science in Sports. https://doi.org/10.1111/sms.70206
Vancouver
Horwitz H, Olesen RH, Windfeld-Mathiasen J, Dalhoff KP, Andersen JT, Middelboe M, et al. Healthcare Costs Associated With Anabolic Steroid Use: A Cohort Study. Scandinavian Journal of Medicine & Science in Sports. 2026. doi:10.1111/sms.70206
BibTeX
@article{Horwitz2026,
author = {Horwitz, Henrik and Olesen, Renée Hangaard and Windfeld-Mathiasen, Josefine and Dalhoff, Kim Peder and Andersen, Jon Trærup and Middelboe, Magnus and Ehlers, Lars Holger and Heerfordt, Ida M},
title = {Healthcare Costs Associated With Anabolic Steroid Use: A Cohort Study},
journal = {Scandinavian Journal of Medicine & Science in Sports},
year = {2026},
doi = {10.1111/sms.70206}
}
EUVIMED